In this issue of Cell, Kenchappa et al. and Radnai et al. report the development of selective non-muscle myosin II inhibitors that show therapeutic potential in glioblastoma and methamphetamine use disorder, opening new avenues for targeting cell mechanobiology in challenging diseases.